ストックスクリーナーアプリを入手
2.41
1.26%
0.03
アフターアワーズ：
2.47
0.06
+2.49%
Aptevo Therapeutics Inc (APVO) 最新ニュース
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Increase in Short Interest - Defense World
APVO stock plunges to 52-week low of $2.48 amid steep annual decline - Investing.com Australia
APVO stock plunges to 52-week low of $2.48 amid steep annual decline By Investing.com - Investing.com South Africa
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
Aptevo to Participate in March Conferences - ACCESS Newswire
Can These Two Major Biotech Conferences Unlock Aptevo's Next Growth Phase? - StockTitan
APVO stock plunges to 52-week low, touches $3 mark - Investing.com
APVO stock plunges to 52-week low, touches $3 mark By Investing.com - Investing.com South Africa
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights - ACCESS Newswire
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update - Defense World
Aptevo Therapeutics (APVO) Projected to Post Quarterly Earnings on Tuesday - Defense World
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition - ACCESS Newswire
Roth Capital Brokers Decrease Earnings Estimates for APVO - Defense World
FY2029 Earnings Estimate for APVO Issued By Roth Capital - Defense World
Aptevo Therapeutics files $100M mixed securities shelf - MSN
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Exclusive: Aptevo's Revolutionary Cancer Treatment Achieves 100% Remission RateCEO Interview Alert - StockTitan
Aptevo Therapeutics Inc. (APVO) reports earnings - Quartz
Aptevo Therapeutics Inc. SEC 10-K Report - TradingView
Aptevo Therapeutics reports FY24 EPS ($87.38) vs. ($2,316.83) last year - TipRanks
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update - StockTitan
APVO stock plunges to 52-week low at $3.62 amid steep annual decline - MSN
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 - ACCESS Newswire
APVO stock plunges to 52-week low at $3.62 amid steep annual decline By Investing.com - Investing.com South Africa
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding - ACCESS Newswire
Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale - ACCESS Newswire
Aptevo Therapeutics Showcases Promising Oncology Drug Pipeline - TipRanks
TG Therapeutics (NASDAQ:TGTX) vs. Aptevo Therapeutics (NASDAQ:APVO) Head-To-Head Review - Defense World
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements - ACCESS Newswire
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decline in Short Interest - Defense World
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - ACCESS Newswire
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting - ACCESS Newswire
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - ACCESS Newswire
Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion - ACCESS Newswire
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - ACCESS Newswire
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update - ACCESS Newswire
Aptevo Therapeutics Announces Closing of $2.75 Million Offering - ACCESS Newswire
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - ACCESS Newswire
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering - ACCESS Newswire
Aptevo's Senior Director to Present ADAPTIR Platform at Major Biotech Conference PepTalk 2025 - StockTitan
Trend Tracker for (APVO) - Stock Traders Daily
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year? - Yahoo Finance
Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish - MSN
APVO stock touches 52-week low at $5.1 amid sharp annual decline - Investing.com Australia
Aptevo Therapeutics Inc. Announces 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline Aml Trial - Marketscreener.com
Aptevo reports full remission in AML trial - Investing.com India
0.61%
大文字化:
|
ボリューム (24 時間):